Venture capital firm focused on biotech pioneers exceeds funding target


With its first fund, V-Bio Fund 1, V-Bio Ventures, based in Ghent, Belgium, now has over €185 million under management. The capital, it is said, places him in “a very good position”to finance promising and innovative companies.

The venture capital group’s strategy is to invest in transformative companies in the biotech, pharmaceutical and agricultural sectors, and that, he said, will remain unchanged in this second fund. He also confirmed that he would maintain the privileged partnership he has with the Flemish Institute for Biotechnology (VIB), a research institution that has founded successful biotechnology companies such as Ablynx.

In addition to the collaboration with VIB, V-Bio Ventures seeks outstanding start-ups focused on therapeutics or diagnostic therapies from other leading academic institutes across Europe.

Since its founding in 2015, the venture capital firm has invested in 19 companies, co-founded seven, and helped advance eight therapies in clinical development and get closer to patients. Recent portfolio successes include Syndesi Therapeutics, which was acquired earlier this year by AbbVie for up to $1 billion.

V-Bio has already invested in the next generation of Belgian biotechnology companies such as Confo, Orionis, Agomab, Aphea.Bio, Exevir, Precirix and Protealis, as well as in companies from other European countries, including Muna, Coave, Oxular and Corteria. .

Team expansion

The Belgian company has also expanded its team, which now includes nine investment professionals. Shelley Margetson joins V-Bio as Managing Partner. She brings significant expertise to the investment group given her senior executive roles at several European biotech companies, including Nasdaq-listed Merus, investors said.

Ward Capoen, who has worked for V-Bio Ventures since the launch of the first fund, is promoted to partner.

Christina Takke and Willem Broekaert, founding managing partners of V-Bio Ventures, said: “We look forward to continuing our proven strategy of investing early in new or young companies based on exceptional science and supporting their management teams through the initial stages of value creation.”


About Author

Comments are closed.